{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:15:04Z","timestamp":1794244504538,"version":"4.9.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA266298-01A1"],"award-info":[{"award-number":["1R01CA266298-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA266298-01A1"],"award-info":[{"award-number":["1R01CA266298-01A1"]}],"id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.seminhematol.2024.01.015","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T16:27:22Z","timestamp":1707323242000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic targeting of apoptosis in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-287X","authenticated-orcid":false,"given":"Inhye E.","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.015_bib0001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.01.015_bib0002","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.015_bib0003","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.015_bib0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.015_bib0006","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2007-07-098681","article-title":"BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism","volume":"111","author":"Majid","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.015_bib0007","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.humpath.2012.07.005","article-title":"Chronic lymphocytic leukemia with t(14;18)(q32;q21)","volume":"44","author":"Tang","year":"2013","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.015_bib0008","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"39","key":"10.1053\/j.seminhematol.2024.01.015_bib0009","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.01.015_bib0010","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood.2020009088","article-title":"miR-15a\/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms","volume":"137","author":"Sewastianik","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0011","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.V92.1.234.413k22_234_240","article-title":"Chromosomal and gene amplification in diffuse large B-cell lymphoma","volume":"92","author":"Rao","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.015_bib0012","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.V90.3.1168","article-title":"BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma","volume":"90","author":"Monni","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Invest"},{"issue":"9059","key":"10.1053\/j.seminhematol.2024.01.015_bib0014","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(96)11103-X","article-title":"BCL-2 antisense therapy in patients with non-Hodgkin lymphoma","volume":"349","author":"Webb","year":"1997","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.015_bib0015","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O'Brien","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.015_bib0016","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3109\/10428194.2015.1048441","article-title":"Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia","volume":"56","author":"Brown","year":"2015","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0017","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2008-02-138560","article-title":"AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance","volume":"113","author":"Balakrishnan","year":"2009","journal-title":"Blood"},{"issue":"7042","key":"10.1053\/j.seminhematol.2024.01.015_bib0018","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.015_bib0019","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.015_bib0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.015_bib0021","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leukemia Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.015_bib0022","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.015_bib0023","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.015_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.015_bib0025","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.015_bib0026","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase ii pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.015_bib0027","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.01.015_bib0028","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.01.015_bib0029","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.015_bib0030","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.015_bib0032","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.015_bib0033","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/bjh.15666","article-title":"Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor","volume":"185","author":"Wierda","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.015_bib0034","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.015_bib0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.015_bib0036","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia","volume":"133","author":"Flinn","year":"2019","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.01.015_bib0037","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2023.41.16_suppl.7512","article-title":"SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL","volume":"41","author":"Crombie","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.015_bib0038","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.015_bib0039","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"34","key":"10.1053\/j.seminhematol.2024.01.015_bib0040","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.015_bib0041","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.015_bib0042","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0043","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood-2021-153033","article-title":"ReVenG: a phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.01.015_bib0044","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.015_bib0045","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.015_bib0046","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular cytotoxicity of next-generation CD20 monoclonal antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0047","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"36","key":"10.1053\/j.seminhematol.2024.01.015_bib0048","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.015_bib0049","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.01.015_bib0050","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.015_bib0051","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.015_bib0052","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.015_bib0053","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"34","key":"10.1053\/j.seminhematol.2024.01.015_bib0054","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clini Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.015_bib0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evidence"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.015_bib0056","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.015_bib0057","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.015_bib0058","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.01.015_bib0059","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.015_bib0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.015_bib0061","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.01.015_bib0062","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.3163_153","article-title":"Long-term follow-up of multicenter phase ii trial of zanubrutinib, obinutuzumab, and venetoclax (Boven) in previously untreated patients with CLL\/SLL","volume":"41","author":"Soumerai","year":"2023","journal-title":"Hematol Oncol."},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0063","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.01.015_bib0064","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2022.40.16_suppl.7540","article-title":"Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL","volume":"40","author":"Rogers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2023-173708","article-title":"Long-term remissions with MRD-guided acalabrutinib, venetoclax and obinutuzumab in relapsed\/refractory CLL: follow-up efficacy and circulating tumor DNA analysis of the CLL2-baag trial","volume":"142","author":"Furstenau","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0066","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2023-173707","article-title":"MRD-guided zanubrutinib, venetoclax and obinutuzumab after an optional debulking with bendamustine in patients with relapsed\/refractory chronic lymphocytic leukemia: primary endpoint analysis of the phase 2 CLL2-Bzag study","volume":"142","author":"Furstenau","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.01.015_bib0067","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2023.41.16_suppl.7500","article-title":"Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)","volume":"41","author":"Woyach","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.015_bib0068","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41375-023-01901-4","article-title":"Venetoclax consolidation in high-risk CLL treated with ibrutinib for >\/=1 year achieves a high rate of undetectable MRD","volume":"37","author":"Thompson","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0069","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/hematology.2022000343","article-title":"Selecting initial therapy in CLL","volume":"2022","author":"Ahn","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.015_bib0070","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.015_bib0071","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.015_bib0072","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"SUPPL 2","key":"10.1053\/j.seminhematol.2024.01.015_bib0073","first-page":"26","article-title":"Genetic markers and outcome in front line obinutuzumab plus chlorambucil or venetoclax - updated analysis of the CLL14 trial","volume":"5","author":"Tausch","year":"2021","journal-title":"HemaSphere"},{"key":"10.1053\/j.seminhematol.2024.01.015_bib0074","first-page":"OF1","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","author":"Jain","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.015_bib0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.015_bib0076","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.01.015_bib0077","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.01.015_bib0078","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.015_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI170169","article-title":"Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies","volume":"133","author":"Chong","year":"2023","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.015_bib0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.015_bib0081","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.015_bib0082","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.01.015_bib0083","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2023.41.16_suppl.7502","article-title":"Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome","volume":"41","author":"Frustaci","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0084","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/blood-2023-185569","article-title":"A prospective, phase-II study to evaluate the efficacy and safety of obinutuzumab, ibrutinib, and venetoclax (GIVeRS) in patients with Richter's syndrome","volume":"142","author":"Tadmor","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0085","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood-2022-160386","volume":"140","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0086","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2022-169662","article-title":"A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with CLL\/SLL: preliminary data","volume":"140","author":"Cheah","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0087","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2023-179541","volume":"142","author":"Tam","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0088","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood-2023-179577","article-title":"A Phase 1 study of the oral CDK9 inhibitor voruciclib in relapsed\/refractory (R\/R) B-cell lymphoma (NHL) or acute myeloid leukemia (AML)","volume":"142","author":"Davids","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0089","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2021-153812","article-title":"VIP152 is a novel CDK9 inhibitor with efficacy in chronic lymphocytic leukemia","volume":"138","author":"Sher","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0090","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.1182\/blood-2022-167651","article-title":"Enitociclib (VIP152\/formerly BAY1251152) is a selective and active CDK9 inhibitor : preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)","volume":"140","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0091","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2022-167203","article-title":"Safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of the cyclin-dependent kinase-9 (CDK9) inhibitor AZD4573 in relapsed\/refractory hematological malignancies: a phase 1 first-in-human study","volume":"140","author":"Brummendorf","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0092","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2023-189711","article-title":"Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 5-year follow-up data","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0093","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.015_bib0094","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2023-177713","article-title":"First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the glow study","volume":"142","author":"Moreno","year":"2023","journal-title":"Blood"},{"issue":"30","key":"10.1053\/j.seminhematol.2024.01.015_bib0095","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:36:49Z","timestamp":1718411809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0037196324000155"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.015","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of apoptosis in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}